# CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

> **NCT00305838** · PHASE2 · UNKNOWN · sponsor: **Mount Vernon Cancer Centre at Mount Vernon Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** tamoxifen citrate
- **OTHER:** diagnostic laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00305838
- **Lead sponsor:** Mount Vernon Cancer Centre at Mount Vernon Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-03
- **Primary completion:** 2008-12
- **Final completion:** —
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305838, "CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00305838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*